E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter

About 50–70% of breast cancers are estrogen receptor α (ERα) positive and most of them are sensitive to endocrine therapy including tamoxifen. However, one third of these patients will eventually develop resistance and relapse. We found that the expression of miR-15a and miR-16 were significantly de...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Junjun, Zhu, Yinghua, Liu, Yujie, Sun, Lijuan, Lv, Xiaobin, Wu, Yanqin, Hu, Pengnan, Su, Fengxi, Gong, Chang, Song, Erwei, Liu, Bodu, Liu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741652/
https://www.ncbi.nlm.nih.gov/pubmed/26397135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741652/
https://www.ncbi.nlm.nih.gov/pubmed/26397135

Ejemplares similares